BEIGENE Trademark

Trademark Overview

On Friday, September 14, 2018, a trademark application was filed for BEIGENE with the United States Patent and Trademark Office. The USPTO has given the BEIGENE trademark a serial number of 88117099. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, June 6, 2022. This trademark is owned by BeiGene, Ltd.. The BEIGENE trademark is filed in the Pharmaceutical Products category with the following description:

Medicines, pharmaceutical preparations, chemico-pharmaceutical preparations, biological preparations for medical purposes, chemical preparations for medical purposes, all of the foregoing for the treatment of cancer and rheumatoid arthritis; diagnostic biomarker reagents for medical purposes
beigene

General Information

Serial Number88117099
Word MarkBEIGENE
Filing DateFriday, September 14, 2018
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, June 6, 2022
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing3000 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, March 5, 2019

Trademark Statements

Description of MarkThe mark consists of a red square divided into four equal quadrants each containing a Chinese character in the color white; the word "BeiGene" in all black letters with the letters "B" and "G" capitalized appears immediately to the right of the red square. The white background is not claimed as part of the mark and represents a transparent background.
Goods and ServicesMedicines, pharmaceutical preparations, chemico-pharmaceutical preparations, biological preparations for medical purposes, chemical preparations for medical purposes, all of the foregoing for the treatment of cancer and rheumatoid arthritis; diagnostic biomarker reagents for medical purposes
Indication of Colors claimedThe color(s) red, white, and black is/are claimed as a feature of the mark.
Transliteration StatementThe non-Latin characters in the mark transliterate to "BAI JI SHEN ZHOU" and this has no meaning in a foreign language.

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, September 21, 2018
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameBeiGene, Ltd.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressGrand Cayman KY1-1108
KY
Party NameBeiGene, Ltd.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressGrand Cayman KY1-1108
KY

Trademark Events

Event DateEvent Description
Monday, June 6, 2022ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, June 6, 2022ABANDONMENT - NO USE STATEMENT FILED
Tuesday, October 26, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, October 25, 2021SOU EXTENSION 5 GRANTED
Thursday, October 21, 2021SOU EXTENSION 5 FILED
Thursday, October 21, 2021SOU TEAS EXTENSION RECEIVED
Wednesday, April 28, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, April 26, 2021SOU EXTENSION 4 GRANTED
Monday, April 26, 2021SOU EXTENSION 4 FILED
Monday, April 26, 2021SOU TEAS EXTENSION RECEIVED
Thursday, February 4, 2021APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Thursday, January 28, 2021TEAS POST PUBLICATION AMENDMENT RECEIVED
Wednesday, October 28, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, October 26, 2020SOU EXTENSION 3 GRANTED
Monday, October 26, 2020SOU EXTENSION 3 FILED
Monday, October 26, 2020SOU TEAS EXTENSION RECEIVED
Monday, May 18, 2020APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Monday, May 18, 2020CASE ASSIGNED TO INTENT TO USE PARALEGAL
Thursday, April 16, 2020TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, April 16, 2020TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Thursday, April 16, 2020ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, April 16, 2020TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Wednesday, March 25, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, March 23, 2020SOU EXTENSION 2 GRANTED
Monday, March 23, 2020SOU EXTENSION 2 FILED
Monday, March 23, 2020SOU TEAS EXTENSION RECEIVED
Thursday, October 17, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, October 15, 2019SOU EXTENSION 1 GRANTED
Tuesday, October 15, 2019SOU EXTENSION 1 FILED
Tuesday, October 15, 2019SOU TEAS EXTENSION RECEIVED
Tuesday, April 30, 2019NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, March 5, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, March 5, 2019PUBLISHED FOR OPPOSITION
Wednesday, February 13, 2019NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, February 6, 2019ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, February 6, 2019TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, January 22, 2019ASSIGNED TO LIE
Saturday, January 5, 2019APPROVED FOR PUB - PRINCIPAL REGISTER
Saturday, January 5, 2019EXAMINER'S AMENDMENT ENTERED
Saturday, January 5, 2019NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Saturday, January 5, 2019EXAMINERS AMENDMENT E-MAILED
Saturday, January 5, 2019EXAMINERS AMENDMENT -WRITTEN
Saturday, January 5, 2019PREVIOUS ALLOWANCE COUNT WITHDRAWN
Saturday, January 5, 2019APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, December 14, 2018NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, December 14, 2018NON-FINAL ACTION E-MAILED
Friday, December 14, 2018NON-FINAL ACTION WRITTEN
Tuesday, December 4, 2018ASSIGNED TO EXAMINER
Saturday, September 22, 2018NOTICE OF DESIGN SEARCH CODE E-MAILED
Friday, September 21, 2018NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, September 18, 2018NEW APPLICATION ENTERED

Related Keywords

beigene preparations medical purposes pharmaceutical rheumatoid diagnostic arthritis biomarker reagents cancer